What is the Medicamen Biotech PE ratio today?
Medicamen Biotech's PE ratio is 33.4 at the 29 October 2026 close (₹266.95 a share): a market capitalisation of ₹362 crore divided by consolidated net profit of ₹10.8 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹9.6 crore) it is 37.6.
What is the Medicamen Biotech debt to equity ratio?
Medicamen Biotech's debt-to-equity ratio was 0.17 on 31 March 2026: borrowings of ₹47.8 crore against total equity of ₹276 crore. A year earlier, on 31 March 2025, it was 0.16.
What is the Medicamen Biotech net worth?
Medicamen Biotech's net worth — shareholders' equity in its consolidated balance sheet — was ₹276 crore on 31 March 2026, up 29.5% from ₹213 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹362 crore at the 29 October 2026 close.
What is the Medicamen Biotech PB ratio (price to book value)?
Medicamen Biotech's price-to-book (PB) ratio is 1.31 at the 29 October 2026 close: a market capitalisation of ₹362 crore divided by shareholders' equity (book value) of ₹276 crore on 31 March 2026. That is a book value of ₹203.17 per share against a share price of ₹266.95.
What is the Medicamen Biotech ROE and ROCE?
In FY26, Medicamen Biotech's return on equity (ROE) was 4.0% and its return on capital employed (ROCE) was 4.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 3.4% and ROCE 3.2%.
What is the Medicamen Biotech book value per share?
Medicamen Biotech's book value per share was ₹203.17 on 31 March 2026: shareholders' equity of ₹276 crore divided by the 1.36 crore shares in issue, up 21.4% from ₹167.35 a year earlier. The share price at the 29 October 2026 close was ₹266.95.
What is the Medicamen Biotech market cap?
Medicamen Biotech's market capitalisation was ₹362 crore at the 29 October 2026 close: 1.36 crore shares at ₹266.95 each.
Is Medicamen Biotech debt free?
No. Medicamen Biotech had borrowings of ₹47.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.17. Its cash and current investments were ₹33.9 crore, so its net debt was ₹13.9 crore.
What is the Medicamen Biotech EPS?
Medicamen Biotech's basic earnings per share (EPS) were ₹7.22 in FY26, against ₹5.16 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹7.41.
What is the Medicamen Biotech dividend yield?
Medicamen Biotech's dividend yield is 0.37% at the 29 October 2026 close: dividends of ₹1 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹266.95. They were ₹1 on 18 September 2026.
What is the Medicamen Biotech promoter holding?
Promoters held 42.57% of Medicamen Biotech on 23 October 2026, up 2.11 percentage points from 40.46% the previous quarter, according to the shareholding pattern filed with NSE.
What is the Medicamen Biotech free cash flow?
In FY26, Medicamen Biotech generated ₹33.2 crore of cash from operations and spent ₹4.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹38 crore. In FY25 it was −₹9.3 crore.
What is the Medicamen Biotech dividend in 2026 and its record date?
In 2026, Medicamen Biotech has declared one dividend: ₹1 with record date 19 September 2026 and ex-date 18 September 2026.
What is the Medicamen Biotech shareholding pattern?
On 23 October 2026, Medicamen Biotech's shares were held by promoters 42.57%, foreign portfolio investors (FII/FPI) 4.35%, domestic institutions (DII) 0.00% (including mutual funds at 0.00%) and retail and other non-institutional investors 53.03%.
When are the Medicamen Biotech next results?
Medicamen Biotech has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What are the Medicamen Biotech latest quarterly results?
Medicamen Biotech's latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹2.1 crore, down 1.6% from ₹2.2 crore in Q1 FY26; revenue from operations ₹47.9 crore, up 11.3% year on year.
What is the Medicamen Biotech revenue and profit in FY26?
In FY26 (April 2025–March 2026), Medicamen Biotech's consolidated net profit was ₹9.6 crore, up 35.6% from ₹7.1 crore in FY25, on revenue from operations of ₹198 crore (up 21.7%). Over three years, from FY23, net profit was down 35.0%.
Medicamen Biotech vs Medico Remedies: how do they compare?
In FY26, Medicamen Biotech earned net profit of ₹9.6 crore on revenue of ₹198 crore, against ₹13.1 crore on ₹206 crore for Medico Remedies. Medicamen Biotech's operating margin was 6.3% (Medico Remedies 6.8%) and its return on equity 4.0% (Medico Remedies 19.0%). At the 29 October 2026 close, Medicamen Biotech's market capitalisation was ₹362 crore against ₹158 crore for Medico Remedies, and its PE ratio on FY26 profit 37.6 against 12.0.
How does Medicamen Biotech compare with its peers?
On FY26 consolidated figures, against Medico Remedies, Aarey Drugs & Pharmaceuticals and Nectar Lifesciences: Medicamen Biotech's return on equity of 4.0% is the second highest of the four (Medico Remedies 19.0%, Aarey Drugs & Pharmaceuticals 2.8%, Nectar Lifesciences −38.1%; peer average −5.4%); its revenue growth over three years of 12.0% a year is the third highest of the four (Medico Remedies 13.7% a year, Aarey Drugs & Pharmaceuticals 96.3% a year, Nectar Lifesciences −81.7% a year; peer average 9.4% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
